Skip to main content
Peptide for Pups

The dogs enrolled

Reading list

Research and veterinary guidance

The papers and official guidance sit together here, with their different jobs intact.

Canine study populations

The first paper to open is Dik and colleagues' senior Golden Retriever study, followed by the BPC-157 safety evaluation alongside the rat and beagle blood-level paper. The glucagon case series changes the setting to dogs receiving hospital care.

The BPC-157 development review and the PubMed searches recorded on September 30, 2026 support the bounded statement that no pet treatment study was found. That search date matters: I would revise the statement if a relevant paper were identified.

Drug guidance and dates

The FDA explanation of animal-drug development, animal-drug questions and federal extra-label rule supply the veterinary context. FDA also explains its concerns about unapproved animal drugs and how to report a suspected problem.

The regulatory records used here were checked on September 30, 2026. That is the date of the check, rather than a date on which any new rule took effect. The animal-drug database remains a record whose contents can change.

Source register

  1. Dik B, et al. Liraglutide as a novel therapeutic for overweight in canines: a clinical study. Vet J 2025;313:106376. ↗
  2. Xu C, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol 2020;114:104665. ↗
  3. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 ... in rats and dogs. Front Pharmacol 2022;13:1026182. ↗
  4. PubMed searches run for this library (GLP-1 drugs and online peptides in dogs, cats and horses) ↗
  5. Mateescu DM, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. ↗
  6. Harris ME, et al. Glucagon therapy in canines with an insulinoma: a retrospective descriptive study of 11 dogs. Can Vet J 2020;61:737-742. ↗
  7. 21 CFR Part 530, Extralabel Drug Use in Animals (sections 530.2, 530.3, 530.13, 530.20, 530.30) ↗
  8. Animal Drugs @ FDA (searchable database of approved and conditionally approved animal drugs) ↗
  9. Frequently Asked Questions about Animal Drugs ↗
  10. FDA's Concerns about Unapproved Animal Drugs ↗
  11. From an Idea to the Marketplace: The Journey of an Animal Drug through the Approval Process ↗
  12. How to Report Animal Drug and Device Side Effects and Product Problems ↗